Clinical Trials Browser

Withdrawn × Hematologic Neoplasms × ceritinib × Clear all

NCT02343679 2017-02-01

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Phase 2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms